IN2014CN04671A - - Google Patents

Download PDF

Info

Publication number
IN2014CN04671A
IN2014CN04671A IN4671CHN2014A IN2014CN04671A IN 2014CN04671 A IN2014CN04671 A IN 2014CN04671A IN 4671CHN2014 A IN4671CHN2014 A IN 4671CHN2014A IN 2014CN04671 A IN2014CN04671 A IN 2014CN04671A
Authority
IN
India
Prior art keywords
compounds
poly
pharmaceutical compositions
present
treating diseases
Prior art date
Application number
Other languages
English (en)
Inventor
Gianluca Mariano Enrico Papeo
Alessandra Cirla
Matteo D’ANELLO
Alessandra Scolaro
Fabio Zuccotto
Original Assignee
Nerviano Medical Sciences Srl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47227787&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IN2014CN04671(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Nerviano Medical Sciences Srl filed Critical Nerviano Medical Sciences Srl
Publication of IN2014CN04671A publication Critical patent/IN2014CN04671A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D217/00Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/24Oxygen atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/472Non-condensed isoquinolines, e.g. papaverine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41881,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/472Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IN4671CHN2014 2011-11-25 2012-11-20 IN2014CN04671A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP11190687 2011-11-25
EP12161489 2012-03-27
PCT/EP2012/073125 WO2013076090A1 (en) 2011-11-25 2012-11-20 3-phenyl-isoquinolin-1(2h)-one derivatives as parp-1 inhibitors

Publications (1)

Publication Number Publication Date
IN2014CN04671A true IN2014CN04671A (es) 2015-09-18

Family

ID=47227787

Family Applications (1)

Application Number Title Priority Date Filing Date
IN4671CHN2014 IN2014CN04671A (es) 2011-11-25 2012-11-20

Country Status (15)

Country Link
US (1) US9422243B2 (es)
EP (1) EP2788328B1 (es)
JP (1) JP6106182B2 (es)
KR (1) KR20140097457A (es)
CN (1) CN103946214B (es)
AU (1) AU2012342562B2 (es)
BR (1) BR112014012031A2 (es)
CA (1) CA2856759A1 (es)
CL (1) CL2014001323A1 (es)
EA (1) EA027800B1 (es)
ES (1) ES2676068T3 (es)
HK (1) HK1200166A1 (es)
IN (1) IN2014CN04671A (es)
MX (1) MX2014006015A (es)
WO (1) WO2013076090A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102104144B1 (ko) 2012-03-07 2020-04-23 디 인스티튜트 오브 캔서 리서치:로얄 캔서 하스피틀 3-아릴-5-치환-이소퀴놀린-1-온 화합물 및 그의 치료적 용도
DK3044221T3 (en) * 2013-09-11 2018-04-23 Institute Of Cancer Res Royal Cancer Hospital The 3-ARYL-5-SUBSTITUTED-ISOQUINOLIN-1-ON COMPOUNDS AND THERAPEUTIC APPLICATION THEREOF
WO2015108986A1 (en) * 2014-01-16 2015-07-23 Clovis Oncology, Inc. Use of parp inhibitors to treat breast or ovarian cancer patients showing a loss of heterozygosity
ES2915266T3 (es) 2015-11-06 2022-06-21 Neurocrine Biosciences Inc Derivados de N-[2-(1-bencilpiperidin-4-il)etil]-4-(pirazin-2-il)-piperazin-1-carboxamida y compuestos relacionados como antagonistas del receptor muscarínico 4 (M4) para el tratamiento de enfermedades neurológicas
WO2023242302A1 (en) 2022-06-15 2023-12-21 Astrazeneca Ab Combination therapy for treating cancer

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002090334A1 (en) * 2001-05-08 2002-11-14 Kudos Pharmaceuticals Limited Isoquinolinone derivatives as parp inhibitors
EP1396488A1 (en) 2001-05-23 2004-03-10 Mitsubishi Pharma Corporation Fused heterocyclic compound and medicinal use thereof
KR20050030636A (ko) * 2002-07-24 2005-03-30 교린 세이야꾸 가부시키 가이샤 4-(치환된 아릴)-5-하이드록시이소퀴놀리논 유도체
AU2009216062B2 (en) * 2008-02-22 2013-02-07 Msd K.K. Novel aminopyridine derivatives having Aurora A selective inhibitory action
TWI499418B (zh) * 2009-05-21 2015-09-11 Nerviano Medical Sciences Srl 異喹啉-1(2h)-酮衍生物

Also Published As

Publication number Publication date
JP2014533709A (ja) 2014-12-15
BR112014012031A2 (pt) 2017-05-30
EA027800B1 (ru) 2017-09-29
CN103946214A (zh) 2014-07-23
AU2012342562A1 (en) 2014-07-10
CN103946214B (zh) 2016-08-17
CA2856759A1 (en) 2013-05-30
HK1200166A1 (en) 2015-07-31
CL2014001323A1 (es) 2014-09-05
AU2012342562B2 (en) 2017-02-23
ES2676068T3 (es) 2018-07-16
US20140336192A1 (en) 2014-11-13
KR20140097457A (ko) 2014-08-06
EP2788328B1 (en) 2018-01-31
US9422243B2 (en) 2016-08-23
EP2788328A1 (en) 2014-10-15
EA201491026A1 (ru) 2014-11-28
MX2014006015A (es) 2014-06-04
JP6106182B2 (ja) 2017-03-29
WO2013076090A1 (en) 2013-05-30

Similar Documents

Publication Publication Date Title
PH12019502809A1 (en) Substituted tricyclic compounds as fgfr inhibitors
MX362939B (es) Derivados de (aza-)isoquinolinona.
MX2014013090A (es) Derivados de pirrolotriazinona.
IN2014KN02601A (es)
PH12014501829A1 (en) Bicyclic pyrazinone derivatives
IN2014MN01875A (es)
MX2015014234A (es) Derivados 2-aminopirido-[4,3-d]pirimidin-5-ona y su uso como inhibidores de wee-1.
MX362855B (es) Derivados de quinazolinona como inhidores poli (adp-ribosa) polimerasa (parp).
MX367425B (es) Derivados de 4-carboxamido-isoindolinona como inhibidores selectivos de parp-1.
PH12014501581A1 (en) Tetrahydro-quinazolinone derivatives as tank and parp inhibitors
SG10201805392YA (en) 1,2,4-triazine-6-carboxamide kinase inhibitors
MX2016001134A (es) Derivados 1,3-disustituidos de ciclopentano.
MX2016008042A (es) Derivados de imidazopirazinona.
IN2014CN04671A (es)
MX2016001536A (es) Derivados de urea de piperidinas.
DOP2014000141A (es) Derivados de quinolina como inhibidores de la enzima pde10a
MX369393B (es) Derivados de ftalazina.
MX2016001934A (es) Derivados de ciclopentilamina 3-sustituidos.
PH12016502133A1 (en) Substituted tricycle compounds as fgfr inhibitors